A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.

Cyrill A Rentsch; George N Thalmann; Ilaria Lucca; Maciej Kwiatkowski; Grégory J Wirth; Räto T Strebel; Daniel Engeler; Augusto Pedrazzini; Clemens Hüttenbrink; Wolfgang Schultze-Seemann; Raimund Torpai; Lukas Bubendorf; Andreas Wicki; Beat Roth; Piet Bosshard; Heike Püschel; Daniel T Boll; Lukas Hefermehl; Florian Roghmann; Michael Gierth; Karin Ribi; Simon Schäfer; Stefanie Hayoz

doi:10.1016/j.euo.2021.12.006

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.

Cyrill A Rentsch
, George N Thalmann
, Ilaria Lucca
, Maciej Kwiatkowski
, Grégory J Wirth
, Räto T Strebel
, Daniel Engeler
, Augusto Pedrazzini
, Clemens Hüttenbrink (Co-author)
, Wolfgang Schultze-Seemann
, Raimund Torpai
, Lukas Bubendorf
, Andreas Wicki
, Beat Roth
, Piet Bosshard
, Heike Püschel
, Daniel T Boll
, Lukas Hefermehl
, Florian Roghmann
, Michael Gierth

Karin Ribi, Simon Schäfer, Stefanie Hayoz

Department of Urology

Research output: Contribution to journal › Original Article › peer-review

27 Citations (Web of Science)

Original language	English
Pages (from-to)	195-202
Journal	EUROPEAN UROLOGY ONCOLOGY
Volume	5
Issue number	2
DOIs	https://doi.org/10.1016/j.euo.2021.12.006
Publication status	Published - 2022

Keywords

MULTICENTER
STRAIN

Access to Document

10.1016/j.euo.2021.12.006

Cite this

Rentsch, C. A., Thalmann, G. N., Lucca, I., Kwiatkowski, M., Wirth, G. J., Strebel, R. T., Engeler, D., Pedrazzini, A., Hüttenbrink, C., Schultze-Seemann, W., Torpai, R., Bubendorf, L., Wicki, A., Roth, B., Bosshard, P., Püschel, H., Boll, D. T., Hefermehl, L., Roghmann, F., ... Hayoz, S. (2022). A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. EUROPEAN UROLOGY ONCOLOGY, 5(2), 195-202. https://doi.org/10.1016/j.euo.2021.12.006

@article{36002c025e5d4c87959fd71970bc3a39,

title = "A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Gu{\'e}rin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.",

keywords = "MULTICENTER, STRAIN",

author = "Rentsch, \{Cyrill A\} and Thalmann, \{George N\} and Ilaria Lucca and Maciej Kwiatkowski and Wirth, \{Gr{\'e}gory J\} and Strebel, \{R{\"a}to T\} and Daniel Engeler and Augusto Pedrazzini and Clemens H{\"u}ttenbrink and Wolfgang Schultze-Seemann and Raimund Torpai and Lukas Bubendorf and Andreas Wicki and Beat Roth and Piet Bosshard and Heike P{\"u}schel and Boll, \{Daniel T\} and Lukas Hefermehl and Florian Roghmann and Michael Gierth and Karin Ribi and Simon Sch{\"a}fer and Stefanie Hayoz",

note = "H{\"u}ttenbrink: Department of Urology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany",

year = "2022",

doi = "10.1016/j.euo.2021.12.006",

language = "English",

volume = "5",

pages = "195--202",

journal = "EUROPEAN UROLOGY ONCOLOGY",

issn = "2588-9311",

publisher = "Elsevier ",

number = "2",

}

Rentsch, CA, Thalmann, GN, Lucca, I, Kwiatkowski, M, Wirth, GJ, Strebel, RT, Engeler, D, Pedrazzini, A, Hüttenbrink, C, Schultze-Seemann, W, Torpai, R, Bubendorf, L, Wicki, A, Roth, B, Bosshard, P, Püschel, H, Boll, DT, Hefermehl, L, Roghmann, F, Gierth, M, Ribi, K, Schäfer, S & Hayoz, S 2022, 'A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.', EUROPEAN UROLOGY ONCOLOGY, vol. 5, no. 2, pp. 195-202. https://doi.org/10.1016/j.euo.2021.12.006

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14. / Rentsch, Cyrill A; Thalmann, George N; Lucca, Ilaria et al.
In: EUROPEAN UROLOGY ONCOLOGY, Vol. 5, No. 2, 2022, p. 195-202.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.

AU - Rentsch, Cyrill A

AU - Thalmann, George N

AU - Lucca, Ilaria

AU - Kwiatkowski, Maciej

AU - Wirth, Grégory J

AU - Strebel, Räto T

AU - Engeler, Daniel

AU - Pedrazzini, Augusto

AU - Hüttenbrink, Clemens

AU - Schultze-Seemann, Wolfgang

AU - Torpai, Raimund

AU - Bubendorf, Lukas

AU - Wicki, Andreas

AU - Roth, Beat

AU - Bosshard, Piet

AU - Püschel, Heike

AU - Boll, Daniel T

AU - Hefermehl, Lukas

AU - Roghmann, Florian

AU - Gierth, Michael

AU - Ribi, Karin

AU - Schäfer, Simon

AU - Hayoz, Stefanie

N1 - Hüttenbrink: Department of Urology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany

PY - 2022

Y1 - 2022

KW - MULTICENTER

KW - STRAIN

U2 - 10.1016/j.euo.2021.12.006

DO - 10.1016/j.euo.2021.12.006

M3 - Original Article

C2 - 35012889

SN - 2588-9311

VL - 5

SP - 195

EP - 202

JO - EUROPEAN UROLOGY ONCOLOGY

JF - EUROPEAN UROLOGY ONCOLOGY

IS - 2

ER -